Vaxart Begins Clinical Trials for Oral Norovirus Vaccine

Norovirus, a highly contagious virus that causes gastroenteritis, has been causing significant outbreaks in both the UK and Canada this winter, with reports of severe cases and prolonged effects on gut health. Experts warn that while most recover within days, some individuals may develop post-infectious irritable bowel syndrome (PI-IBS) and other long-term health issues. In South Korea, researchers have identified a native plant with potential antiviral properties against norovirus, paving the way for future health supplements. Meanwhile, the FDA is working to enhance berry safety to prevent contamination with norovirus and hepatitis A. Additionally, Vaxart, Inc. has launched a Phase 1 clinical trial for a second-generation oral norovirus vaccine, addressing a critical public health need as the virus continues to spread. These developments highlight the ongoing challenges and research focus surrounding norovirus and its impact on public health.